Again, based on the present interaction space, and considering that both receptor binding domains in the virus' spike protein and their corresponding binding sites in ACE2 may exhibit significant conformational flexibility, we may now come up with a few possible interaction "scenarios" for the two viruses -which will, in turn, help us establish important practical conclusions regarding the latter's overall ACE2 affinities (Table ). First, if we assume that all interactions may indeed reach their maximum value for both viruses (scenario I), then SARS-CoV can be expected to bind to ACE2 with a slightly greater (~6%) overall affinity; however, and since this scenario should clearly not be perceived as having exclusive biochemical significance -additional scenarios must obviously be considered as well. In scenario II, minimum values are considered for all investigated interactions. 2019-nCoV, in this case, is clearly the "winner" -as the sum of its interactions amounts to ~350% of the corresponding sum for SARS-CoV. That being said, it should be stressed that interactions derived from the crystal structure of SARS-CoV-ACE2 (that is, n-SARS-a) -which can be expected to represent lower bounds for interactions 1, 2 and 4 -are likely to bias this scenario in favor of 2019-nCoV. Still, and since the statistical dispersion measures are larger for SARS-CoV even in case where crystal structure geometries are not considered (see Table ) -it is possible to expect 2019-nCoV to bind to ACE2 with higher affinity in the current scenario. If we consider the average value of all investigated interactions for each virus as a measure for overall ACE2 affinity (scenario III), then 2019-nCoV is shown to have the upper hand (larger by ~26% than the average interaction for SARS-CoV). Similarly, summing the average value for each individual interaction (scenario IV) gives 2019-nCoV an advantage of ~34%. However, removing the aforementioned, somewhat-biased crystal-structure-derived energetics from our averaging (V and VI) -SARS-CoV clearly exhibits superior statistics (values are larger than those for 2019-nCoV by ~20% and ~18%, respectively).